Dangel V, Giray J, Ratge D, Wisser H
Department of Clinical Pathology, Robert Bosch Hospital, Stuttgart, Germany.
Biochem J. 1996 Aug 1;317 ( Pt 3)(Pt 3):925-31. doi: 10.1042/bj3170925.
The regulation of the expression of beta-adrenoceptor (beta-ARs) is not thoroughly understood. We demonstrate that the rat heart cell-line H9c2 expresses both beta 1- and beta 2-ARs. In radioligand-binding experiments, the maximal binding capacity of (-)-[125I]-iodocyanopindolol was determined as 18 +/- 0.6 fmol/mg of protein with a KD of 35.4 +/- 4.1 pM. Competitive radioligand-binding experiments with subtype-specific beta-antagonists reveal a subtype ratio of beta 1- to beta 2-ARs of 29%: 71%. With competitive reverse-transcriptase PCR we found beta 2-mRNA to be up to 1600 times more frequent than beta 1-mRNA. Treatment of the H9c2 cell-line with the beta-adrenergic agonist (-)-isoproterenol (10(-6) M), the antagonist (-)-propranolol (10(-6) M) and the glucocorticoid dexamethasone (500 nM) induces regulatory effects on both the beta-AR protein and mRNA level. Isoproterenol treatment leads to down-regulation of the total receptor number by 56 +/- 4%, due to a decrease in beta 2-ARs, while maintaining the beta 1-AR number constant. On the transcription level, both beta 1-and beta 2-mRNAs are decreased by 30% and 42% respectively. mRNA stability measurements reveal a reduced half-life of beta 2-mRNA from 9.3 h to 6.5 h after isoproterenol treatment. Incubation of cells with (-)-propranolol does not affect the amounts of beta-ARs and their mRNAs. Dexamethasone induces a 1.8 +/- 0.2-fold increase in beta-AR number over the basal level as well as a 1.9 +/- 0.2-fold increase in the amount of beta 2-mRNA. Because the half-life of beta 2-mRNA was unaffected by dexamethasone, the increased beta 2-mRNA level must be due to an enhanced transcription rate. The beta 1-mRNA levels are unchanged during dexamethasone-incubation of the cells. Our data clearly demonstrate that treatment of H9c2 rat heart cells with isoproterenol and dexamethasone induces alterations in the level of RNA stability as well as gene transcription, leading to altered receptor numbers.
β-肾上腺素能受体(β-ARs)表达的调控机制尚未完全明确。我们发现大鼠心脏细胞系H9c2同时表达β1-和β2-肾上腺素能受体。在放射性配体结合实验中,(-)-[125I]-碘氰吲哚洛尔的最大结合容量为18±0.6 fmol/mg蛋白质,解离常数KD为35.4±4.1 pM。用亚型特异性β拮抗剂进行的竞争性放射性配体结合实验显示,β1-与β2-肾上腺素能受体的亚型比例为29%:71%。通过竞争性逆转录聚合酶链反应,我们发现β2- mRNA的表达频率比β1- mRNA高1600倍。用β-肾上腺素能激动剂(-)-异丙肾上腺素(10^-6 M)、拮抗剂(-)-普萘洛尔(10^-6 M)和糖皮质激素地塞米松(500 nM)处理H9c2细胞系,对β-AR蛋白和mRNA水平均有调节作用。异丙肾上腺素处理导致总受体数量下调56±4%,这是由于β2-肾上腺素能受体数量减少,而β1-肾上腺素能受体数量保持不变。在转录水平上,β1-和β2- mRNA分别减少30%和42%。mRNA稳定性测量显示,异丙肾上腺素处理后,β2- mRNA的半衰期从9.3小时缩短至6.5小时。用(-)-普萘洛尔孵育细胞不影响β-ARs及其mRNA的含量。地塞米松使β-AR数量比基础水平增加1.8±0.2倍,β2- mRNA含量增加1.9±0.2倍。由于地塞米松不影响β2- mRNA的半衰期,β2- mRNA水平的增加一定是由于转录速率提高所致。在细胞用地塞米松孵育期间,β1- mRNA水平没有变化。我们的数据清楚地表明,用异丙肾上腺素和地塞米松处理H9c2大鼠心脏细胞会导致RNA稳定性水平以及基因转录发生改变,从而导致受体数量改变。